Sarepta Therapeutics Announces Pipeline Progress For Multiple Limb-Girdle Muscular Dystrophy Programs
April 15 (Reuters) - Sarepta Therapeutics Inc SRPT.O:
SAREPTA THERAPEUTICS ANNOUNCES PIPELINE PROGRESS FOR MULTIPLE LIMB-GIRDLE MUSCULAR DYSTROPHY PROGRAMS
SAREPTA THERAPEUTICS INC: DATA EXPECTED FOR SRP-9003 FOR LGMD2E/R4 BY MID-2025
SAREPTA THERAPEUTICS INC: U.S. FDA HAS CONFIRMED THAT SCREENING AND DOSING MAY PROCEED IN STUDY SRP-9005-101 FOR LGMD2C/R5
SAREPTA THERAPEUTICS INC: ENROLLMENT AND DOSING COMPLETED IN STUDY SRP-9004-102 FOR LGMD2D/R3
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Microsoft 2026 Q3 Earnings Preview: Can Azure’s Growth Momentum Keep Up With Massive AI Capital Spending?

Deep Analysis 48 Hours Before Microsoft Earnings: OpenAI Agreement Restructuring Implemented, Three Variables of Azure, Copilot, and Capital Expenditure Determine MSFT Valuation Recovery Path

MSTR Stock Price Prediction 2026-2030: Is Strategy the Ultimate Bitcoin Leveraged Play?

SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Nvidia Shares Hit Record High, Market Cap Tops $526 Trillion, How Much Higher Can It Go Amid AI Capex Boom?

Tradingkey







